Gerken G, Manns M, Kyriatsoulis A, Hess G, Meyer zum Büschenfelde K H
I. Medizinische Klinik der Johannes-Gutenberg-Universität Mainz.
Z Gastroenterol. 1988 Jul;26(7):374-9.
The immunogenicity and efficacy of different commercially available vaccines against hepatitis B virus (HBV) has been demonstrated in a number of controlled vaccination trials throughout the world. However, the significance of pre-S proteins in hepatitis B vaccines is still controversially discussed. Therefore, a radioimmunoassay (RIA) was developed to detect pre-S proteins in HBsAg-carriers as well as in different hepatitis B vaccines. This study confirmed the high amount of pre-S proteins as well as poly-albumin receptors in purified Dane particles and sera of patients with acute hepatitis B. The currently available plasma derived vaccine H-B-Vax and the recombinant hepatitis B vaccines Gen H-B-Vax and Engerix B yielded negative results in pre-S- and poly-albumin-receptor-RIAs. The plasma derived vaccine Hevac B Pasteur included pre-S encoded proteins. Future vaccination trials in man have to evaluate the role of pre-S antigens and antibodies in the pathogenesis and the protection of hepatitis B infection including recombinant pre-S vaccines which are under development.
全球多项对照疫苗接种试验已证明了不同市售乙型肝炎病毒（HBV）疫苗的免疫原性和有效性。然而，乙型肝炎疫苗中前S蛋白的意义仍存在争议。因此，开发了一种放射免疫分析法（RIA）来检测HBsAg携带者以及不同乙型肝炎疫苗中的前S蛋白。本研究证实了急性乙型肝炎患者的纯化丹氏颗粒和血清中存在大量前S蛋白以及多聚白蛋白受体。目前可用的血浆源性疫苗H-B-Vax以及重组乙型肝炎疫苗Gen H-B-Vax和Engerix B在前S和多聚白蛋白受体RIA中均呈阴性结果。血浆源性疫苗Hevac B Pasteur含有前S编码蛋白。未来针对人类的疫苗接种试验必须评估前S抗原和抗体在乙型肝炎感染的发病机制及保护作用中的作用，包括正在研发的重组前S疫苗。
